Topic collection

Gut peptide medicines

A benefit in people with severe intestinal failure does not prove that a product heals the gut in general.

1 peptide record1 with Established evidence3 fact checks

Start here

Start with these posts

Separate the FDA-approved medicine for short bowel syndrome from broad claims about gut repair, inflammation, and wellness.

Peptide records

Open each record to see its evidence.

Compare evidence ↗

Health results for approved uses
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use in the reviewed sources. It does not mean the product is safe or effective for everyone.
Teduglutide
An established medicine that can reduce support given through a vein in short bowel syndrome. It needs intensive product-specific monitoring.
3 fact checks · Open the review ↗

More about this topic

One reviewed peptide sits in this family: teduglutide, graded Established, with an FDA-approved product for short bowel syndrome. The studied patients depended on parenteral support, such as nutrition or fluids given outside the normal digestive route, and the measured benefit was a reduction in that support.

This is a narrow, closely monitored setting. A result showing better absorption in people with severe intestinal failure does not prove general gut healing, lower inflammation, or wellness benefits. The page below keeps that limit clear.

Questions to ask about this topic

01
Did patients need nutrition or fluids outside the normal digestive route?
02
What meaningful reduction in that support was measured?
03
What screening and monitoring were required because of how the medicine works?